Cargando…
Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke
AIM: To study the diagnostic and prognostic role of serum galectin-1 (Gal-1) and -3 (Gal-3) in acute ischemic stroke (AIS) patients. METHODS: We enrolled 233 patients with first-ever acute ischemic stroke and 252 healthy controls in this study. The AIS severity was evaluated by National Institutes o...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752558/ https://www.ncbi.nlm.nih.gov/pubmed/29312645 http://dx.doi.org/10.18632/oncotarget.18211 |
_version_ | 1783290131781779456 |
---|---|
author | Dong, Han Wang, Zhi-Hao Zhang, Na Liu, Si-Da Zhao, Jian-Jun Liu, Song-Yan |
author_facet | Dong, Han Wang, Zhi-Hao Zhang, Na Liu, Si-Da Zhao, Jian-Jun Liu, Song-Yan |
author_sort | Dong, Han |
collection | PubMed |
description | AIM: To study the diagnostic and prognostic role of serum galectin-1 (Gal-1) and -3 (Gal-3) in acute ischemic stroke (AIS) patients. METHODS: We enrolled 233 patients with first-ever acute ischemic stroke and 252 healthy controls in this study. The AIS severity was evaluated by National Institutes of Health Stroke Scale (NIHSS) scores. The serum Gal-1 and -3 levels were determined. All patients were followed for 1 years and the functional outcome were evaluated by modified Rankin Scale (mRS) scores. RESULTS: We found that AIS patients had higher serum Gal-1 and -3 levels than controls. The serum Gal-3 level was closely associated with the AIS severity indicated by NHSS and infarction volume. Serum Gal-3 levels were significantly higher in patients with a poor outcome indicated by mRS scores than those in patients with a good outcome. In contrast, the serum Gal-1 is not associated with the severity and outcome of acute AIS patients. Our in vitro studies show that Gal-3 knockdown with siRNA dramatically increased the culture neuron cell viability and reduced apoptosis under oxygen glucose deprivation treatment. Meanwhile, the pro-inflammatory cytokine expression decreased with the inhibition of Gal-3. CONCLUSION: Our finding provides a novel biological marker, serum Gal-3, for monitor of acute AIS patients. |
format | Online Article Text |
id | pubmed-5752558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-57525582018-01-08 Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke Dong, Han Wang, Zhi-Hao Zhang, Na Liu, Si-Da Zhao, Jian-Jun Liu, Song-Yan Oncotarget Clinical Research Paper AIM: To study the diagnostic and prognostic role of serum galectin-1 (Gal-1) and -3 (Gal-3) in acute ischemic stroke (AIS) patients. METHODS: We enrolled 233 patients with first-ever acute ischemic stroke and 252 healthy controls in this study. The AIS severity was evaluated by National Institutes of Health Stroke Scale (NIHSS) scores. The serum Gal-1 and -3 levels were determined. All patients were followed for 1 years and the functional outcome were evaluated by modified Rankin Scale (mRS) scores. RESULTS: We found that AIS patients had higher serum Gal-1 and -3 levels than controls. The serum Gal-3 level was closely associated with the AIS severity indicated by NHSS and infarction volume. Serum Gal-3 levels were significantly higher in patients with a poor outcome indicated by mRS scores than those in patients with a good outcome. In contrast, the serum Gal-1 is not associated with the severity and outcome of acute AIS patients. Our in vitro studies show that Gal-3 knockdown with siRNA dramatically increased the culture neuron cell viability and reduced apoptosis under oxygen glucose deprivation treatment. Meanwhile, the pro-inflammatory cytokine expression decreased with the inhibition of Gal-3. CONCLUSION: Our finding provides a novel biological marker, serum Gal-3, for monitor of acute AIS patients. Impact Journals LLC 2017-05-25 /pmc/articles/PMC5752558/ /pubmed/29312645 http://dx.doi.org/10.18632/oncotarget.18211 Text en Copyright: © 2017 Dong et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Clinical Research Paper Dong, Han Wang, Zhi-Hao Zhang, Na Liu, Si-Da Zhao, Jian-Jun Liu, Song-Yan Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke |
title | Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke |
title_full | Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke |
title_fullStr | Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke |
title_full_unstemmed | Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke |
title_short | Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke |
title_sort | serum galectin-3 level, not galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke |
topic | Clinical Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752558/ https://www.ncbi.nlm.nih.gov/pubmed/29312645 http://dx.doi.org/10.18632/oncotarget.18211 |
work_keys_str_mv | AT donghan serumgalectin3levelnotgalectin1isassociatedwiththeclinicalfeatureandoutcomeinpatientswithacuteischemicstroke AT wangzhihao serumgalectin3levelnotgalectin1isassociatedwiththeclinicalfeatureandoutcomeinpatientswithacuteischemicstroke AT zhangna serumgalectin3levelnotgalectin1isassociatedwiththeclinicalfeatureandoutcomeinpatientswithacuteischemicstroke AT liusida serumgalectin3levelnotgalectin1isassociatedwiththeclinicalfeatureandoutcomeinpatientswithacuteischemicstroke AT zhaojianjun serumgalectin3levelnotgalectin1isassociatedwiththeclinicalfeatureandoutcomeinpatientswithacuteischemicstroke AT liusongyan serumgalectin3levelnotgalectin1isassociatedwiththeclinicalfeatureandoutcomeinpatientswithacuteischemicstroke |